| |
![[Collapse]](/DXR.axd?r=1_10-bacL7) | Group: Cell-depleting antibodies |
| | | Sub-Group: |
| | | | Target: CD16 |
| | | | Depleting anti-CD16 | 3G8: Mouse anti-human CD16, NK cell-depleting antibody. (Available only in 200mg units at 10mg/ml.) |
| | | | Target: CD20 |
| | | | Depleting anti-CD20 (rhesus recombinant) | CD20-2B8R1: mouse/rhesus CDR-grafted form of the depleting anit-CD20 antibody, rituximab. |
| | | | Target: CD3 |
| | | | CD3-immunotoxin | Recombinant CD3 (FN18) diphtheria toxin. Fusion protein composed of an affinity-matured form of FN18 expressed as a single chain diabody DT fusion protein (Prot Eng Design Select 2007; 20: 425) |
| | | | Target: CD4 |
| | | | Depleting anti-CD4 (human recombinant) | huOKT4A: Humanized, depleting anti-CD4 antibody. REAGENT WILL BE DISCONTINUED AFTER JANUARY 2011. |
| | | | Depleting anti-CD4 (rhesus recombinant) | CD4R1: Rhesus recombinant CDR-grafted anti-CD4 antibody. Rhesus IgG1 heavy chain. (Replaces humanized OKT4A.) |
| | | | Target: CD8 |
| | | | Depleting anti-CD8alpha (rhesus recombinant) | M-T807R1: mouse/rhesus CDR-grafted form of the depleting anti-CD8a antibody, M-T807. (Available only in 200mg units at 10mg/ml.) |
| | | | Depleting anti-CD8beta (rhesus recombinant) | CD8b255R1: Rhesus recombinant CDR-grafted anti-CD8b antibody [New Reagent] |
| | | | Target: Rhesus anti-Thymocyte Globulin |
| | | | Anti-rhesus Thymocyte Globulin | Purified rabbit IgG from serum of rabbits
immunized with rhesus thymocytes. Available to NIH Investigators only. |
| Group: Control antibodies |
| | | Sub-Group: |
| | | | Target: |
| | | | Control antibody: Human/mouse chimeric | Recombinant control antibody, 1129. V-regions from a mouse anti-RSV antibody; C-regions from human IgG1K. |
| | | | Control antibody: Rhesus recombinant IgG1 | Rhesus IgG1 with CDRs grafted from an irrelevant (anti-desmipramine) monoclonal antibody. Serves as an irrelevant control antibody for other rhesus recombinant antibodies such as anti-CD8 |
| | | | Control antibody: Human IgG1 | Control Human IgG1: Fully human antibody directed against an irrelevant antigen (a bacterial toxin). |
| | | | Control antibody: Mouse IgG1 | Control mouse IgG1. Antibody is directed against an irrelevant antigen (a bacterial toxin). (Available only in 200mg units at 10mg/ml.) |
| Group: Other antibodies |
| | | Sub-Group: |
| | | | Target: |
| | | | Anti-alpha-4/beta-7 integrin | Recombinant anti-alpha4/beta7 integrin engineered as a rhesus IgG1 |
| | | | Human IFN-gamma R/Ig fusion protein | Human IFN-gamma receptor fused to human IgG2 Fc |
| | | | Target: CD154 |
| | | | Human/mouse chimeric anti-CD154 | Recombinant anti-CD154 antibody. V-regions from mouse 5C8 clone; C-regions human IgG1k. |
| | | | Mouse anti-CD154 (NC8A4) | Mouse monoclonal antibody, NC8A4, against CD154. In vivo activity undetermined. |
| | | | Target: CD2 |
| | | | Anti-CD2, LoCD2bR1 | Rhesus recombinant antibody based on the CDRs of
the rat anti-primate anti-CD2 antibody, LoCD2b. |
| | | | Target: CD40 |
| | | | Anti-CD40 (2C10R1, recombinant) | Rhesus recombinant (chimeric) form of 2C10. Constant regions are rhesus IgG1k. |
| | | | Anti-CD40 (2C10R4, recombinant) | Rhesus recombinant (chimeric) form of 2C10. Constant regions are rhesus IgG4k. |
| | | | Anti-CD40 (3A8R1, recombinant) | Rhesus recombinant (chimeric) form of 3A8. Constant regions are rhesus IgG1k. |
| | | | Anti-CD40 (3A8R4, recombinant) | Rhesus recombinant (chimeric) form of 3A8. Constant regions are rhesus IgG4k. |
| | | | Anti-CD40 (mouse 3A8) | 3A8: Mouse antibody against macaque CD40. |
| | | | Target: IL-10 |
| | | | Anti-IL-10 (rhesus recombinant) | Rhesus recombinant (CDR-grafted) antibody that neutralizes rhesus IL-10 in vivo and in vitro |
| | | | Target: IL-15 |
| | | | Anti-IL-15 (rhesus recombinant) | Rhesus recombinant (CDR-grafted) antibody that neutralizes rhesus IL-15 in vitro and in vivo |
| | | | Target: PD-1 |
| | | | Anti-PD-1 (rhesus recombinant) | Rhesus recombinant antibody (rhesus/human chimeric)
comprising silenced rhesus IgG4k constant regions and variable regions from
anti-human PD-1, nivolumab. |
| | | | Anti-PD-1 (rhesus recombinant) | Recombinant
antibody comprising rhesus IgG4*k constant regions and variable regions from the
anti-PD-1 antibody pembrolizumab. |
